Latest News & Publications
CyteQuest Presents at the 28th ASGCT Annual Meeting in New Orleans
Dr. Michael Stehnach presented a poster detailing our latest smaller, faster microfluidic electroporation platform, which uses low-volume samples to rapidly optimize cell gene-editing parameters and can be seamlessly scaled for high-volume manufacturing.
CyteQuest Receives $2 Million SBIR Phase II Funding to Scale High-Throughput Electroporation for Advanced Cellular Therapies
CyteQuest has been awarded $2 million in SBIR Phase II funding to scale its high-throughput, non-viral electroporation platform, addressing a key bottleneck in the production of complex cellular therapies.
CyteQuest Presents at the 27th ASGCT Annual Meeting in Baltimore
Dr. Harold Craighead unveiled new scientific data via poster presentation, showing the performance gains delivered by the latest iteration of the company’s proprietary flow electroporation technology.
CyteQuest Publishes New Article in Biomedical Microdevices
CyteQuest publishes an article featuring the capabilities of our electroporation platform for flexible, 8-channel multiplexed optimization in Biomedical Microdevices titled, “A multiplexed microfluidic continuous-flow electroporation system for efficient cell transfection.”
CyteQuest Showcases Flow Electroporation Platform at BIO International Convention 2023 in Boston
Supported by the NIH SEED program, Dr. Stephen Levy attended the convention to showcase CyteQuest’s proprietary flow electroporation technology to potential partners and investors.
CyteQuest Presents at the 26th ASGCT Annual Meeting in Los Angeles
Dr. Jacob VanderBurgh presented a poster detailing the latest advancements in CyteQuest’s proprietary flow electroporation technology.
CyteQuest Publishes New Article in Scientific Reports
CyteQuest publishes an article featuring the capabilities of its proprietary flow technology in Scientific Reports titled, “Scalable continuous-flow electroporation platform enabling T cell transfection for cellular therapy manufacturing.
CyteQuest Presents at the Cornell NanoScale Facility’s 2022 Annual Meeting
Dr. Jacob VanderBurgh engages with the local nanoscale community at Cornell University and presents its proprietary flow electroporation chip design at the CNF 2022 Annual Meeting.
CyteQuest Presents at BPI’s Biotech Week Boston 2022
Dr. Jacob VanderBurgh showcases data from transfection of primary T cells in a poster presentation at Biotech Week Boston in the Cell & Gene Therapy Manufacturing section.
CyteQuest Receives Over $275,000 in SBIR Funding to Advance Non-Viral Cell Engineering Technology
CyteQuest has been awarded over $275,000 in SBIR Phase I funding to develop a new generation of non-viral cell engineering technology. The grant will support the creation of a simple, scalable electroporation platform designed to overcome the limitations of viral vectors in cellular therapy production.
CyteQuest Raises $1.1 Million in New Equity Investment
CyteQuest secured $1.1 million in new equity investment to accelerate the development of its proprietary flow electroporation technology, a non-viral solution poised to transform cell engineering.